Tryptophan metabolism and immunogenetics in major depression: A role for interferon-γ gene

Brain, Behavior, and Immunity

Volumn 31, Issue , 2013, Pages 128-133

  Myint, Aye Mu ^a,b   Bondy, Brigitta ^a   Baghai, Thomas C ^a   Eser, Daniela ^a   Nothdurfter, Caroline ^a   Schüle, Cornelius ^a   Zill, Peter ^a   Müller, Norbert ^a   Rupprecht, Rainer ^a   Schwarz, Markus J ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Affective disorder; Genetics; Interferon gamma; Kynurenine pathway; SNP; Tryptophan breakdown

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ANTIDEPRESSANT AGENT; GAMMA INTERFERON; KYNURENINE; SEROTONIN; TRYPTOPHAN;

ADULT; ALLELE; AMINO ACID METABOLISM; ARTICLE; CONTROLLED STUDY; FEMALE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; IMMUNOGENETICS; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESISTANT DEPRESSION;

ADULT; AGED; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; HYDROXYINDOLEACETIC ACID; IMMUNOGENETICS; INTERFERON-GAMMA; KYNURENINE; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; SEROTONIN; TRYPTOPHAN;

EID: 84878123960     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2013.04.003     Document Type: Article

References (52)

1. Aberg-Wistedt A., Hasselmark L., Stain-Malmgren R., Aperia B., Kjellman B.F., Mathe A.A. Serotonergic 'vulnerability' in affective disorder: a study of the tryptophan depletion test and relationships between peripheral and central serotonin indexes in citalopram-responders. Acta Psychiatr. Scand. 1998, 97:374-380.
2. Anisman H., Ravindran A.V., Griffiths J., Merali Z. Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features. Mol. Psychiatry 1999, 4:182-188.
3. Asnis G.M., Sachar E.J., Halbreich U., Nathan R.S., Novacenko H., Ostrow L.C. Cortisol secretion in relation to age in major depression. Psychosom. Med. 1981, 43:235-242.
4. Asnis G.M., Sachar E.J., Halbreich U., Nathan R.S., Ostrow L., Halpern F.S. Cortisol secretion and dexamethasone response in depression. Am. J. Psychiatry 1981, 138:1218-1221.
5. Bremner J.D., Innis R.B., Salomon R.M., Staib L.H., Ng C.K., Miller H.L., et al. Positron emission tomography measurement of cerebral metabolic correlates of tryptophan depletion-induced depressive relapse. Arch. Gen. Psychiatry 1997, 54:364-374.
6. Capouron L., Ravaud A., Neveu P.J., Miller A.H., Maes M., Dantzer R. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol. Psychiatry 2002, 7:468-473.
7. Carlin J.M., Borden E.C., Sondel P.M., Byrne G.I. Biologic-response-modifier-induced indoleamine 2,3-dioxygenase activity in human peripheral blood mononuclear cell cultures. J. Immunol. 1987, 139:2414-2418.
8. Carlin J.M., Borden E.C., Sondel P.M., Byrne G.I. Interferon-induced indoleamine 2,3-dioxygenase activity in human mononuclear phagocytes. J. Leukoc. Biol. 1989, 45:29-34.
9. Cohen M.R., Pickar D., Extein I., Gold M.S., Sweeney D.R. Plasma cortisol and beta-endorphin immunoreactivity in nonmajor and major depression. Am. J. Psychiatry 1984, 141:628-632.
10. Connor T.J., Leonard B.E. Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sci. 1998, 62:583-606.
11. Delgado P.L., Charney D.S., Price L.H., Aghajanian G.K., Landis H., Heninger G.R. Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch. Gen. Psychiatry 1990, 47:411-418.
12. Delgado P.L., Price L.H., Miller H.L., Salomon R.M., Licinio J., Krystal J.H., et al. Rapid serotonin depletion as a provocative challenge test for patients with major depression: relevance to antidepressant action and the neurobiology of depression. Psychopharmacol. Bull. 1991, 27:321-330.
13. Delgado P.L., Miller H.L., Salomon R.M., Licinio J., Krystal J.H., Moreno F.A., et al. Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biol. Psychiatry 1999, 46:212-220.
14. Hayaishi O. Properties and function of indoleamine 2,3-dioxygenase. J. Biochem. 1976, 79:13P-21P. (Tokyo).
15. Hayaishi O. Biochemical and Medical Aspect of Tryptophan Metabolism 1980, Elsevier/North-Holland Biomedical, Amsterdam.
16. Heyes M.P., Saito K., Milstien S., Schiff S.J. Quinolinic acid in tumors, hemorrhage and bacterial infections of the central nervous system in children. J. Neurol. Sci. 1995, 133:112-118.
17. Hu B., Hissong B.D., Carlin J.M. Interleukin-1 enhances indoleamine 2,3-dioxygenase activity by increasing specific mRNA expression in human mononuclear phagocytes. J. Interferon Cytokine Res. 1995, 15:617-624.
18. Hughes M.M., Carballedo A., McLoughlin D.M., Amico F., Harkin A., Frodl T., Connor T.J. Tryptophan depletion in depressed patients occurs independent of kynurenine pathway activation. Brain Behav. Immun. 2012, 26(6):979-987.
19. Jun T.Y., Pae C.U., Chae J.H., Bahk W.M., Kim K.S., Han H. Report on IL-10 gene polymorphism at position -819 for major depression and schizophrenia in Korean population. Psychiatry Clin. Neurosci. 2002, 56:177-180.
20. Jun T.Y., Pae C.U., Chae J.H., Bahk W.M., Kim K.S., Pyo C.W., et al. Tumor necrosis factor-beta gene polymorphism may not be associated with major depressive disorder in the Korean population. Psychiatry Clin. Neurosci. 2003, 57:31-35.
21. Jun T.Y., Pae C.U., Hoon H., Chae J.H., Bahk W.M., Kim K.S., et al. Possible association between -G308A tumour necrosis factor-alpha gene polymorphism and major depressive disorder in the Korean population. Psychiatr. Genet. 2003, 13:179-181.
22. Kaestner F., Hettich M., Peters M., Sibrowski W., Hetzel G., Ponath G., et al. Different activation patterns of proinflammatory cytokines in melancholic and non-melancholic major depression are associated with HPA axis activity. J. Affect. Disord. 2005, 87:305-311.
23. Kim Y.K., Suh I.B., Kim H., Han C.S., Lim C.S., Choi S.H., et al. The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs. Mol. Psychiatry 2002, 7:1107-1114.
24. Lanquillon S., Krieg J.C., Ing-Abu-Shach U., Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 2000, 22:370-379.
25. Lapin I.P. Kynurenines as possible participants of depression. Pharmapsychiatry. Neuropsychopharmakol. 1973, 6:273-279.
26. Lapin I.P., Oxenkrug G.F. Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect. Lancet 1969, 1(7586):132-136.
27. Lin S.C., Maruta T., Newman D.C., Kao P.C. Plasma levels of cortisol, corticotropin, and beta-endorphin in patients with major depression. J. Clin. Psychiatry 1986, 47:413-414.
28. Mellor A.L., Munn D.H. Tryptophan catabolism and T-cell tolerance. immunosuppression by starvation?. Immunol. Today 1999, 20:469-473.
29. Mikova O., Yakimova R., Bosmans E., Kenis G., Maes M. Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. Eur. Neuropsychopharmacol. 2001, 11:203-208.
30. Miller C.L., Llenos I.C., Dulay J.R., Barillo M.M., Yolken R.H., Weis S. Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia. Neurobiol. Dis. 2004, 15:618-629.
31. Musso T., Gusella G.L., Brooks A., Longo D.L., Varesio L. Interleukin-4 inhibits indoleamine 2,3-dioxygenase expression in human monocytes. Blood 1994, 83:1408-1411.
32. Myint A.M., Leonard B.E., Steinbusch H.W., Kim Y.K. Th1, Th2, and Th3 cytokine alterations in major depression. J. Affect. Disord. 2005, 88:167-173.
33. Myint A.M., Kim Y.K., Verkerk R., Scharpe S., Steinbusch H., Leonard B. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J. Affect. Disord. 2007, 98:143-151.
34. Oxenkrug G., Perianayagam M., Mikolich D., Requintina P., Shick L., Ruthazer R., Zucker D., Summergrad P. Interferon-gamma (+874) T/A genotypes and risk of IFN-alpha induced depression. J. Neural Transm. 2011, 118(2):271-274.
35. Pravica V., Asderakis A., Perrey C., Hajeer A., Sinnott P.J., Hutchinson I.V. In vitro production of IFN-gamma correlates with CA repeat polymorphism in the human IFN-gamma gene. Eur. J. Immunogenet. 1999, 26:1-3.
36. Raitala A., Pertovaara M., Karjalainen J., Oja S.S., Hurme M. Association of interferon-gamma +874(T/A) single nucleotide polymorphism with the rate of tryptophan catabolism in healthy individuals. Scand. J. Immunol. 2005, 61:387-390.
37. Raitala A., Karjalainen J., Oja S.S., Kosunen T.U., Hurme M. Helicobacter pylori-induced indoleamine 2,3-dioxygenase activity in vivo is regulated by TGFB1 and CTLA4 polymorphisms. Mol. Immunol. 2007, 44:1011-1014.
38. Saito K., Ohta Y., Nagamura Y., Sasaki E., Ishiguro I. Relationship between L-tryptophan uptake and L-tryptophan 2,3-dioxygenase activity in rat hepatocytes. Biochem. Int. 1990, 20:71-80.
39. Salter M., Pogson C.I. The role of tryptophan 2,3-dioxygenase in the hormonal control of tryptophan metabolism in isolated rat liver cells. Effects of glucocorticoids and experimental diabetes. Biochem. J. 1985, 229:499-504.
40. Satyanarayana U., Rao B.S. Dietary tryptophan level and the enzymes of tryptophan NAD pathway. Br. J. Nutr. 1980, 43:107-113.
41. Sher L., Oquendo M.A., Galfalvy H.C., Zalsman G., Cooper T.B., Mann J.J. Higher cortisol levels in spring and fall in patients with major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005, 29:529-534.
42. Simen B.B., Duman C.H., Simen A.A., Duman R.S. TNFalpha signaling in depression and anxiety: behavioral consequences of individual receptor targeting. Biol. Psychiatry 2006, 59:775-785.
43. Smith S.A., Carr F.P., Pogson C.I. The metabolism of L-tryptophan by isolated rat liver cells. Quantification of the relative importance of, and the effect of nutritional status on, the individual pathways of tryptophan metabolism. Biochem. J. 1980, 192:673-686.
44. Smith K.A., Morris J.S., Friston K.J., Cowen P.J., Dolan R.J. Brain mechanisms associated with depressive relapse and associated cognitive impairment following acute tryptophan depletion. Br. J. Psychiatry 1999, 174:525-529.
45. Spillmann M.K., Van der Does A.J., Rankin M.A., Vuolo R.D., Alpert J.E., Nierenberg A.A., et al. Tryptophan depletion in SSRI-recovered depressed outpatients. Psychopharmacology 2001, 155:123-127.
46. Sun Y. Indoleamine 2,3-dioxygenase-a new antioxidant enzyme. Mater. Med. Pol. 1989, 21:244-250.
47. Taylor M.W., Feng G.S. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J. 1991, 5:2516-2522.
48. Thomas A.J., Davis S., Morris C., Jackson E., Harrison R., O'Brien J.T. Increase in interleukin-1beta in late-life depression. Am. J. Psychiatry 2005, 162:175-177.
49. Traskman-Bendz L., Asberg M., Bertilsson L., Thoren P. CSF monoamine metabolites of depressed patients during illness and after recovery. Acta Psychiatr. Scand. 1984, 69:333-342.
50. Wichers M.C., Koek G.H., Robaeys G., Verkerk R., Scharpe S., Maes M. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol. Psychiatry 2005, 10(6):538-544.
51. Yasui H., Takai K., Yoshida R., Hayaishi O. Interferon enhances tryptophan metabolism by inducing pulmonary indoleamine 2,3-dioxygenase: its possible occurrence in cancer patients. Proc. Natl. Acad. Sci. USA 1986, 83:6622-6626.
52. Yu Y.W., Chen T.J., Hong C.J., Chen H.M., Tsai S.J. Association study of the interleukin-1 beta (C-511T) genetic polymorphism with major depressive disorder, associated symptomatology, and antidepressant response. Neuropsychopharmacology 2003, 28:1182-1185.